SELLAS Life Sciences Group, Inc. — Director's Dealing 2018

Mar 16, 2018

SEC Form 4/A — Form 4/A

Issuer: SELLAS Life Sciences Group, Inc. (SLS)
CIK: 0001390478
Period of Report: 2017-12-29

Reporting Person: SCHEINBERG DAVID A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-29	Common Stock	A	9107	—	Acquired	9107	Direct

Footnotes

F1: In connection with the merger of SELLAS Life Sciences Group, Ltd ("SELLAS") and a wholly owned indirect subsidiary of the Issuer (then known as Galena Biopharma, Inc.) (the "Merger"), outstanding restricted stock units ("RSUs") to be settled in SELLAS common shares were assumed by the Issuer and will be settled in shares of the Issuer's common stock based on the following exchange ratio: 43.9972 shares of the Issuer's common stock for each common share of SELLAS.

F2: Represents shares issuable upon vesting of RSUs. The RSUs are subject to, and to vest must satisfy, both (a) performance-based vesting restrictions (the RSUs will satisfy the performance-based vesting restrictions upon a liquidity event as defined in the award agreement) and (b) time-based vesting restrictions (100% of the RSUs satisfied the time-based vesting restrictions on February 27, 2018). The Merger did not constitute a liquidity event for the performance-based vesting restrictions.